{"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}],"groups":[{"description":"Carfilzomib was administered intravenously (IV) at 20 mg/m\\^2 in Cycle 1: days 1 and 2; at 56 mg/m\\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.\n\nDexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles.","id":"BG000","title":"Kd - Carfilzomib and Dexamethasone"},{"description":"Carfilzomib was administered intravenously (IV) at 20 mg/m\\^2 in Cycle 1: days 1 and 2; at 56 mg/m\\^2 in Cycle 1: days 8, 9, 15 and 16. The 56 mg/m\\^2 dosage was continued in Cycles 2+ on days 1, 2, 8, 9, 15 and 16.\n\nDexamethasone was taken by IV infusion at 20 mg on Cycle 1, days 1 and 2 (in Cycles 2+, days 1 and 2 could be either oral or IV) and either orally or by IV infusion on days 8, 9, 15 and 16 and at 40 mg on day 22 of all 28-day cycles. The administration of dexamethasone was given on carfilzomib and/or daratumumab IV infusion days.\n\nDaratumumab was administered by IV at 8 mg/kg on Cycle 1: days 1 and 2; at 16 mg/kg on Cycle 1: days 8, 15 and 22, and Cycle 2: days 1, 8, 15, and 22. The 16 mg/kg dosage was continued on Cycles 3-6: days 1 and 15. The 16 mg/kg dosage was continued on Cycles 7+: day 1 only.","id":"BG001","title":"KdD - Carfilzomib, Dexamethasone and Daratumumab"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.6","value":"64.3"},{"groupId":"BG001","spread":"10.0","value":"62.9"},{"groupId":"BG002","spread":"9.9","value":"63.4"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"163"},{"groupId":"BG002","value":"240"}],"title":"18 - 64 years"},{"measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"121"},{"groupId":"BG002","value":"176"}],"title":"65 - 74 years"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"50"}],"title":"75 - 84 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":">=85 years"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"63"},{"groupId":"BG001","value":"135"},{"groupId":"BG002","value":"198"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"177"},{"groupId":"BG002","value":"268"}],"title":"Male"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"146"},{"groupId":"BG001","value":"291"},{"groupId":"BG002","value":"437"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"21"}],"title":"Unknown or Not Reported"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"66"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"9"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"123"},{"groupId":"BG001","value":"243"},{"groupId":"BG002","value":"366"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"25"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"68"},{"groupId":"BG001","value":"176"},{"groupId":"BG002","value":"244"}],"title":"Fit"},{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"90"}],"title":"Intermediate fitness"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"19"}],"title":"Frail"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"103"}],"title":"Not available"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"10"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Frailty Status as Assessed by Investigator","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"147"},{"groupId":"BG001","value":"295"},{"groupId":"BG002","value":"442"}],"title":"Disease status 0 or 1"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"22"}],"title":"Disease status 2"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}],"title":"Missing"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"description":"A scale to assess a patient's disease status. 0 = Fully active, able to carry out all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity, ambulatory and able to carry out work of a light nature; 2 = Ambulatory and capable of all self care, unable to carry out any work activities. Up and about \\> 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair \\> 50% of waking hours; 4 = Completely disabled, confined to bed or chair; 5 = Dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"36.57","value":"44.03"},{"groupId":"BG001","spread":"34.69","value":"47.86"},{"groupId":"BG002","spread":"35.34","value":"46.58"}]}],"denoms":[{"counts":[{"groupId":"BG000","value":"149"},{"groupId":"BG001","value":"297"},{"groupId":"BG002","value":"446"}],"units":"Participants"}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","populationDescription":"Data was not available for some participants.","title":"Time from Initial Diagnosis to Randomization","unitOfMeasure":"months"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"74"}],"title":"High risk"},{"measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"164"}],"title":"Standard risk"},{"measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"156"},{"groupId":"BG002","value":"228"}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"description":"The high-risk group consists of the genetic subtypes t(4; 14), t(14; 16), or deletion17p.\n\nThe standard-risk group consists of participants without t(4; 14), t(14; 16), and deletion 17p.\n\nThe unknown risk group is participants with FISH result not done, failed or quantity was not sufficient.","paramType":"COUNT_OF_PARTICIPANTS","title":"Risk Group as Determined by Fluorescent in situ Hybridization (FISH)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"127"},{"groupId":"BG001","value":"252"},{"groupId":"BG002","value":"379"}],"title":"Stage I or II"},{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"87"}],"title":"Stage III"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"description":"The International Staging System (ISS) for myeloma was published by the International Myeloma Working Group (a lower stage indicates less progressed disease):\n\nStage I: β2-microglobulin (β2M) \\< 3.5 mg/L, albumin \\>= 3.5 g/dL Stage II: β2M \\< 3.5 mg/L and albumin \\< 3.5 g/dL; or β2M 3.5 mg/L - 5.5 mg/L irrespective of the serum albumin Stage III: β2M ≥ 5.5 mg/L. Higher stages indicate more advanced disease and/or poorer prognosis.\n\nData is the ISS result assessed at the time of randomization using an interactive voice/web response system (IxRS).","paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: International Staging System (ISS) Stage per IxRS","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"67"},{"groupId":"BG001","value":"133"},{"groupId":"BG002","value":"200"}],"title":"1 prior treatment"},{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"179"},{"groupId":"BG002","value":"266"}],"title":"> = 2 prior treatments"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"description":"Number of participants grouped by total number of prior regimens. Data reported are randomization stratification values.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: Lines of Prior Treatment per IxRS","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"139"},{"groupId":"BG001","value":"279"},{"groupId":"BG002","value":"418"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"48"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"description":"The number of participants with prior proteasome inhibitor treatment assessed at the time of randomization per the IxRS. Data reported are randomization stratification values.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: Prior Proteasome Inhibitor Treatment per IxRS","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"311"},{"groupId":"BG002","value":"465"}],"title":"No"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"description":"The number of participants with prior CD38 antibody therapy assessed at the time of randomization per the IxRS. Data reported are randomization stratification values.","paramType":"COUNT_OF_PARTICIPANTS","title":"Stratification Factor: Prior CD38 Antibody Therapy per IxRS","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"33"}],"title":"North America"},{"measurements":[{"groupId":"BG000","value":"103"},{"groupId":"BG001","value":"207"},{"groupId":"BG002","value":"310"}],"title":"Europe"},{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"84"},{"groupId":"BG002","value":"123"}],"title":"Asia Pacific"}],"denoms":[{"counts":[{"groupId":"BG000","value":"154"},{"groupId":"BG001","value":"312"},{"groupId":"BG002","value":"466"}],"units":"Participants"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Geographic Regions","unitOfMeasure":"Participants"}],"populationDescription":"Intent to Treat population"}